Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 1/20 | 0.44 |
| ▸ | ELOC | Q15369 | 1/20 | 0.44 |
| ▸ | ELOB | Q15370 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 3/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8470635 | 0.82 | VHL (0.46) | VHLELOCELOBKDM4EHTT | |
| SCHEMBL30543404 | 0.82 | VHL (0.46) | VHLELOCELOBKDM4EHTT | |
| SCHEMBL10464 | 0.75 | MAPT (0.46) | VHLELOCELOBKDM4EHTT | |
| SCHEMBL28387239 | 0.72 | VHL (0.44) | VHLELOCELOBKDM4EHTT | |
| SCHEMBL6924 | 0.71 | NOTUM (0.39) | VHLELOCELOBKDM4EHTT | |
| SCHEMBL28972015 | 0.71 | HPGD (0.41) | VHLELOCELOBKDM4EHTT | |
| SCHEMBL8346491 | 0.71 | VHL (0.41) | VHLELOCELOBKDM4EHTT | |
| SCHEMBL30437990 | 0.71 | HPGD (0.41) | VHLELOCELOBKDM4EHTT | |
| SCHEMBL67587 | 0.68 | VHL (0.54) | VHLELOCELOBKDM4EHTT | |
| SCHEMBL22253606 | 0.68 | MAOA (0.41) | KDM4EALDH1A1MAPTL3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234962-A1 | OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230234962-A1 | OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20220401422-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-alpha AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-22 | — | — | US | disclosed |
| WO-2022007924-A1 | OXA-AZABICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2022-01-13 | — | — | WO | disclosed |
| WO-2021217508-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2α AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401422-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-alpha AND THEIR METHODS OF USE | HIF1AN, HIF1A, EGLN2 | VHL 5/4885ELOC 583/4885ELOB 178/4885 |
| US-20230234962-A1 | OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | PIK3CD, PIK3CA, PIK3R5 | VHL 1179/4885ELOC 4339/4885ELOB 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.